The economic burden of psoriatic diseases in Taiwan

Journal of Dermatological Science

Volumn 75, Issue 3, 2014, Pages 183-189

  Chen, Kuan Chen ^a   Hung, Sheng Tzu ^a   Yang, Ching Wen Wendy ^b   Tsai, Tsen Fang ^c   Tang, Chao Hsiun ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b University of California   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cost of illness; Economic burdens; National Health Insurance; Psoriasis; Taiwan

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS; STATISTICAL MODEL; TAIWAN; COST OF ILLNESS; ECONOMICS; HOSPITAL ADMISSION; MIDDLE AGED; OUTPATIENT; PUBLIC HEALTH; QUALITY OF LIFE; YOUNG ADULT;

ADULT; AGED; COST OF ILLNESS; ECONOMICS, HOSPITAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OUTPATIENTS; PATIENT ADMISSION; PSORIASIS; QUALITY OF LIFE; TAIWAN; YOUNG ADULT;

EID: 84905019261     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.05.012     Document Type: Article

References (23)

1. Tsai T.F., Wang T.S., Hung S.T., Tasi P.I., Schenkel B., Zhang M., et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011, 63:40-46.
2. Chen H.H., Tseng M.P., Tsai T.F. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica 2003, 21:216-224.
3. Crown W.H., Bresnahan B.W., Orsini L.S., Kennedy S., Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004, 20:1929-1936.
4. Li K., Armstrong A.W. A review of health outcomes in patients with psoriasis. Dermatol Clin 2012, 30:61-72.
5. Yu A.P., Tang J., Xie J., Wu E.Q., Gupta S.R., Bao Y., et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009, 25:2429-2438.
6. Beyer V., Wolverton S.E. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010, 146:46-54.
7. Berger K., Ehlken B., Kugland B., Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005, 3:511-518.
8. Carrascosa J.M., Pujol R., Daudén E., Hernanz-Hermosa J.M., Bordas X., Smandia J.A., et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006, 20:840-845.
9. Schöffski O., Augustin M., Prinz J., Rauner K., Schubert E., Sohn S., et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007, 5:209-218.
10. Colombo G., Altomare G., Peris K., Martini P., Quarta G., Congedo M., et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manage 2008, 4:559-568.
11. National Health Research Institutes.
12. Hsiao F.Y., Yang C.L., Huang Y.T., Huang W.F. Using Taiwan's national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal 2007, 15:99-108.
13. Kimball A.B., Yu A.P., Signorovitch J., Xie J., Tsaneva M., Gupta S.R., et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012, 66:67-76.
14. Ghatnekar O., Ljungberg A., Wirestrand L.E., Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol 2012, 22:238-245.
15. Javitz H.S., Ward M.M., Farber E., Nail L., Vallow S.G. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46:850-860.
16. Gunnarsson C., Chen J., Rizzo J.A., Ladapo J.A., Naim A., Lofland J.H. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatol 2012, 23:240-254.
17. Navarini A.A., Laffitte E., Conrad C., Piffaretti P., Brock E., Ruckdaescheld S., et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010, 140:85-91.
18. Chan B., Hales B., Shear N., Ho V., Lynde C., Poulin Y., et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009, 13:192-197.
19. Jacobs P., Bissonnette R., Guenther L.C. Socioeconomic burden of immune-mediated inflammatory diseases: focusing on work productivity and disability. J Rheumatol Suppl 2011, 88:55-61.
20. Meyer N., Paul C., Feneron D., Bardoulat I., Thiriet C., Camara C., et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010, 24:1075-1082.
21. Fowler J.F., Duh M.S., Rovba L., Buteau S., Pinheiro L., Lobo F., et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008, 59:772-780.
22. Sohn S., Schoeffski O., Prinz J., Reich K., Schubert E., Waldorf K., et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006, 212:137-144.
23. Kimball A.B., Guerin A., Tsaneva M., Yu A.P., Wu E.Q., Gupta S.R., et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011, 25:157-163.